secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENSAR, Inc. (LNSR)
CIK:        0001320350
Form:       8-K
Filed at:   2022-06-13T23:59:59+00:00
Accession:  0001564590-22-023044
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LENSAR receives FDA 510(k) clearance for ALLY Adaptive Cataract Treatment System
--------------------------------------------------------------------------------

- FDA 510(k) clearance received on June 9, 2022 for next-generation ALLY system.
- ALLY is first FDA-cleared platform for femtosecond-laser cataract surgery in a single sterile environment.
- Initial controlled launch planned for Q3 2022; wider availability targeted in 2023.
- Over 125 surgeons experienced ALLY during live demonstrations at ASRS and company office.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1320350/000156459022023044/0001564590-22-023044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1320350/000156459022023044/lnsr-8k_20220609.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-023044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer